4:15 PM - 4:30 PM (EDT), Monday, June 5, 2023 ・ Session Room 104C
Shaperon is a clinical stage biotech company developing novel inflammasome inhibitors(small molecule). Its unique mechanism of action of GPCR19-P2X7 modulation suppresses a broad spectrum of inflammatory cytokines including IL-1β, IL-18, IL-6, and TNF-α, etc. by controlling both priming and activation phase of inflammasome, whereas conventional approaches are designed to suppress only the activation phase. We are currently developing multiple clinical programs in atopic dermatitis, cytokine release syndrome, Alzheimer’s disease, ulcerative colitis, NASH, etc.
In addition to inflammasome R&D programs, Shaperon has anti-cancer nanobody bispecifics and anti-viral nanobody therapeutics. Shaperon’s proprietary immunized nanobody libraries combined with high throughput screening and in vitro/in vivo system enable us to fast forward the realization of advantages of nanobodies over conventional antibody-based medicines.
KRX (Korea Exchange)
Company Type:
Publicly Traded Company
Company HQ State:
Company HQ Country:
Korea, Republic of
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided